Descriptions:
Vivaglobin® is the first FDA-approved, 16% subcutaneous (Sub-Q) immunoglobulin therapy available for primary immunodeficiency patients.
vivaglobin, pidd, primary immunodeficiency, primary immunodeficiency disorder, immunodeficiency, immunodeficiency disorder